Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Prochlorperazine

FDA-approved product (suppository, rectal), marketed as Compazine, Compro, Prochlorperazine and 3 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Prochlorperazine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Anxiety disorder
  • Nausea and vomiting
  • Psychosis
  • Schizophrenia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Phenothiazines with piperazine structure
FDA pharmacologic class
Phenothiazine FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA39.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli42.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae13.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis74.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Prochlorperazine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Prochlorperazine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Staccato Prochlorperazine in Migraine (in Clinic)

    NCT00610428 · start 2005-03

    Registered record
    Registry ID
    NCT00610428
    Conditions
    Migraine Headache, With or Without Aura
    Interventions
    Staccato Placebo; Staccato Prochlorperazine 5 mg; Staccato Prochlorperazine 10 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-03
    Completion
    2005-10
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine Headache, With or Without Aura
    InterventionStaccato Placebo; Staccato Prochlorperazine 5 mg; Staccato Prochlorperazine 10 mg
    PhasePhase 2
    Registry statusCompleted

  • Staccato Prochlorperazine Single Dose PK Study

    NCT00610727 · start 2004-08

    Registered record
    Registry ID
    NCT00610727
    Conditions
    Migraine
    Interventions
    Prochlorperazine 0.5 mg IV over 5 sec; Inhaled prochlorperazine 0.625 mg; Inhaled prochlorperazine 1.25 mg; Inhaled prochlorperazine 2.5 mg; Inhaled prochlorperazine 5 mg; Inhaled prochlorperazine 10 mg; Inhaled placebo; Prochlorperazine 10 mg IV over 5 sec
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2004-08
    Completion
    2004-10
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionProchlorperazine 0.5 mg IV over 5 sec; Inhaled prochlorperazine 0.625 mg; Inhaled prochlorperazine 1.25 mg; Inhaled prochlorperazine 2.5 mg +4 more
    PhasePhase 1
    Registry statusCompleted

  • Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer

    NCT00020657 · start 2001-07

    Registered record
    Registry ID
    NCT00020657
    Conditions
    Nausea and Vomiting; Unspecified Adult Solid Tumor, Protocol Specific
    Interventions
    dolasetron mesylate; granisetron hydrochloride; ondansetron; prochlorperazine; quality-of-life assessment
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-07
    Completion
    2004-10
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNausea and Vomiting; Unspecified Adult Solid Tumor, Protocol Specific
    Interventiondolasetron mesylate; granisetron hydrochloride; ondansetron; prochlorperazine +1 more
    PhasePhase 3
    Registry statusCompleted

  • Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

    NCT00001337 · start 1993-05-08

    Registered record
    Registry ID
    NCT00001337
    Conditions
    Diffuse Large B-Cell Lymphoma (DLBCL); Primary Mediastinal Large B-cell Lymphoma; Burkitt Lymphoma; Anaplastic Large-Cell Lymphoma; Gray Zone Lymphoma
    Interventions
    Etoposide; Rituximab; Prednisone; Cyclophosphamide; Vincristine; Doxorubicin; MRI; CT; Biopsy; PET scan; Laparotomy; Ondansetron; Prochlorperazine; Omeprazole; Docusate Sodium + Sennosides; Lactulose
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1993-05-08
    Completion
    2024-05-24
    Enrolment
    348

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiffuse Large B-Cell Lymphoma (DLBCL); Primary Mediastinal Large B-cell Lymphoma; Burkitt Lymphoma; Anaplastic Large-Cell Lymphoma +1 more
    InterventionEtoposide; Rituximab; Prednisone; Cyclophosphamide +12 more
    PhasePhase 2
    Registry statusCompleted

  • Bioavailability of Prochlorperazine Suppositories, 25 mg

    NCT00992472

    Registered record
    Registry ID
    NCT00992472
    Conditions
    Healthy
    Interventions
    Prochlorperazine suppositories, 25mg; Compazine® suppositories, 25mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionProchlorperazine suppositories, 25mg; Compazine® suppositories, 25mg
    PhasePhase 1
    Registry statusCompleted